Publications on Pentahibe®

  • Low molecular weight carbohydrate Pentaisomaltose® may replace DMSO as a safer cryoprotectant for cryopreservation of peripheral blood stem cells, Svalgaard JD. et. Al, Transfusion 2016 
    Link to article
  • Pentaisomaltose®, an Alternative to DMSO. Engraftment of Cryopreserved Human CD34+ Cells in Immunodeficient NSG Mice, Svalgaard JD. et. Al. July 2018, Cell Transplantation 27(7) 
    Link to article
  • Cryopreservation of adipose-derived stromal/stem cells using 1–2% Me2SO (DMSO) in combination with Pentaisomaltose®: An effective and less toxic alternative to comparable freezing media, Svalgaard JD. et. al. June 2020, Cryobiology 
    Link to article
  • DMSO (Me2SO) concentrations of 1-2% in combination with pentaisomaltose are effective for cryopreservation of T cells” Eva Kannik Haastrup et al. Transfusion and Apheresis Science 2021
    Link to article

Other Publications 

  • Safety of dextran in relation to other colloids-ten years’ experience with hapten inhibition, Ljungstrom KG, 1993 
    Link to article 
  • Results: PentaHibe® demonstrated favorable results, which are currently pending publication. Data are available on file for discussion under a confidentiality agreement.

 

 

  • icon-approved.svg

    Approved

    Pharmacosmos is the only dextran manufacturer holding certificates from the US FDA and European Directorate for the Quality of Medicines (EDQM)

  • icon-Quality.svg

    Quality Delivered

    Pharmacosmos delivers a unique dextran quality through a production technology that completely avoids the use of organic solvents and a quality system that meets the strictest cGMP standards for human medicines

  • icon-global.svg

    Global Service

    Pharmacosmos sells and ships directly to clients everywhere in the World. We deliver Pharmaceutical Quality Dextran of the highest standards, including those of the European Pharmacopoeia (EP), the United States Pharmacopoeia (USP), and the Japanese Pharmacopoeia (JP).